Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma. (January 2013)

• Record Type: Journal Article
• Authors: Salama, April K.S.
• Is Part Of: Clinical medicine insights. Oncology. Volume 7(2013)
• Publication Date: 2013-01
• Subjects: metastatic melanoma -- therapy -- ipilimumab -- PD-1 -- BRAF -- MEK -- KIT; Oncology -- Periodicals; 616.994005
• DOI: 10.4137/CMO.S9565
• Languages: English
• ISSNs: 1179-5549

Abstract

Metastatic melanoma remains a difficult disease to treat, and long term survivors are rare. Over the past few years, however, breakthroughs in both immunotherapy as well as targeted agents have had a tremendous impact on patients diagnosed with this disease. This review summarizes recent advances in systemic therapies for melanoma, including immune modulators directed against cytotoxic T lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), as well as a number of targeted agents. These approaches hold great promise as the landscape of therapeutic options for advanced melanoma continues to evolve.